Aboagye EO - Search Results

1

Kinetic filtering of [(18)F]Fluorothymidine in positron emission tomography studies.

Gray KR, Contractor KB, Kenny LM, Al-Nahhas A, Shousha S, Stebbing J, Wasan HS, Coombes RC, Aboagye EO, Turkheimer FE, Rosso L. Gray KR, et al. Among authors: aboagye eo. Phys Med Biol. 2010 Feb 7;55(3):695-709. doi: 10.1088/0031-9155/55/3/010. Epub 2010 Jan 13. Phys Med Biol. 2010. PMID: 20071760

2

Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer.

Aboagye EO, Saleem A, Cunningham VJ, Osman S, Price PM. Aboagye EO, et al. Cancer Res. 2001 Jul 1;61(13):4937-41. Cancer Res. 2001. PMID: 11431319

3

Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients.

Aboagye EO, Luthra SK, Brady F, Poole K, Anderson H, Jones T, Boobis A, Burtles SS, Price P. Aboagye EO, et al. Br J Cancer. 2002 Apr 8;86(7):1052-6. doi: 10.1038/sj.bjc.6600212. Br J Cancer. 2002. PMID: 11953847 Free PMC article.

4

Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography.

Hutchinson OC, Collingridge DR, Barthel H, Price PM, Aboagye EO. Hutchinson OC, et al. Among authors: aboagye eo. Curr Pharm Des. 2003;9(11):917-29. doi: 10.2174/1381612033455288. Curr Pharm Des. 2003. PMID: 12678875 Review.

5

Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography.

Hutchinson OC, Collingridge DR, Barthel H, Price PM, Aboagye EO. Hutchinson OC, et al. Among authors: aboagye eo. Curr Pharm Des. 2003;9(11):931-44. doi: 10.2174/1381612033455251. Curr Pharm Des. 2003. PMID: 12678876 Review.

6

2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337.

Wells P, Aboagye E, Gunn RN, Osman S, Boddy AV, Taylor GA, Rafi I, Hughes AN, Calvert AH, Price PM, Newell DR. Wells P, et al. J Natl Cancer Inst. 2003 May 7;95(9):675-82. doi: 10.1093/jnci/95.9.675. J Natl Cancer Inst. 2003. PMID: 12734319

7

Metabolic activation of temozolomide measured in vivo using positron emission tomography.

Saleem A, Brown GD, Brady F, Aboagye EO, Osman S, Luthra SK, Ranicar AS, Brock CS, Stevens MF, Newlands E, Jones T, Price P. Saleem A, et al. Among authors: aboagye eo. Cancer Res. 2003 May 15;63(10):2409-15. Cancer Res. 2003. PMID: 12750260

8

3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.

Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, Luthra SK, Brady F, Price PM, Aboagye EO. Barthel H, et al. Among authors: aboagye eo. Cancer Res. 2003 Jul 1;63(13):3791-8. Cancer Res. 2003. PMID: 12839975

9

Use of positron emission tomography in anticancer drug development.

Aboagye EO, Price PM. Aboagye EO, et al. Invest New Drugs. 2003 May;21(2):169-81. doi: 10.1023/a:1023521412787. Invest New Drugs. 2003. PMID: 12889738 Review.

10

In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography.

Barthel H, Wilson H, Collingridge DR, Brown G, Osman S, Luthra SK, Brady F, Workman P, Price PM, Aboagye EO. Barthel H, et al. Among authors: aboagye eo. Br J Cancer. 2004 Jun 1;90(11):2232-42. doi: 10.1038/sj.bjc.6601862. Br J Cancer. 2004. PMID: 15150578 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

303 results

Search Page

Filters